Treace Medical Concepts, Inc., an orthopedic medical device company, is dedicated to the design, manufacture, and marketing of biological devices and / or solutions for foot and ankle surgeons in the United States. The company is headquartered in Ponte Vedra Beach, Florida.
| Revenue (TTM) | $205.31M |
| Gross Profit (TTM) | $163.12M |
| EBITDA | $-46.35M |
| Operating Margin | -33.00% |
| Return on Equity | -72.00% |
| Return on Assets | -17.30% |
| Revenue/Share (TTM) | $3.19 |
| Book Value | $1.04 |
| Price-to-Book | 4.10 |
| Price-to-Sales (TTM) | 1.32 |
| EV/Revenue | 1.484 |
| EV/EBITDA | -40.95 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -4.20% |
| Shares Outstanding | $65.03M |
| Float | $47.84M |
| % Insiders | 25.23% |
| % Institutions | 49.46% |
Volatility is currently expanding
Treace Medical Concepts NASDAQ: TMCI reported a 4% decline in third-quarter revenue as a shift toward lower-priced products and lower bunion procedure kit sales offset growth in procedure volumes. The company narrowed its full-year revenue outlook and said it expects to return to growth in the fourth quarter.
Treace Medical Concepts (TMCI) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.26 per share a year ago.
PONTE VEDRA, Fla., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company with the goal of being the recognized leader in the surgical treatment of bunions and other foot & ankle conditions, today reported financial results for the third quarter ended September 30, 2026.
New solution for 5ᵗʰ metatarsal deformities further broadens portfolio and provides access to incremental surgical procedures New solution for 5ᵗʰ metatarsal deformities further broadens portfolio and provides access to incremental surgical procedures
PONTE VEDRA, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced it will present at the Stifel 2026 Healthcare Conference, Wednesday, November 11, 2026, beginning at approximately 1:20 pm ET.
PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2026 before the start of trading on Friday, November 6, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.
PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and other foot & ankle conditions, today announced the presentation of the results from three clinical studies at the American Orthopaedic Foot & Ankle Society (“AOFAS”) Annual Meeting in Seattle, Washington. The presentations include data on the milestone 5-year ALIGN3D® Lapiplasty®, the MTA3D® Adductoplasty® and the SPRINT™ SpeedPlate® clinical studies.
New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
Treace Medical Concepts NASDAQ: TMCI reported second-quarter 2026 revenue of $45.4 million, down 4% from the prior-year period, as lower procedure-kit sales to stocking distributors and a continued shift toward lower-priced minimally invasive products weighed on reported sales.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TMCI and any ticker you trade — then tracks every position and per-strategy win rate.
